Member Info for Moneymunch

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,789 followers

1d

The #biotech space is cluttered with many companies claiming to be on the cutting edge, with little to back this up. Genflow Biosciences (LON:GENF) (OTCQB:GENFF), on the other hand, stands out in numerous ways.

Differentiating between the true innovators and the rest can be difficult. That's why we've created a new fact sheet summarizing our exciting research that aims to extend both human and canine #healthspan.

What sets #GENF apart:

✅ Long life IP, protecting our #SIRT6 centenarian gene & gene delivery research

✅ Creating #MASH treatment to address untapped market of 35 million people

✅ Lead by experienced team with a background running public companies

Learn more about #Genflow: htTps://loom.ly/qLRb1jE

Hi Laura, i've held PYC in the past and been a while since i last looked. This coming year for Genflow should see a significant rise in fortunes as they deliver positive news on progress made. They're currently in the process of preparing "Proof of Concept" for their upcomming dog trial which is expected to take 6 months or so, and if successful should lead to an early lucrative licensing deal with their Vet Partner, and of course there's plenty more newsflow likely on the rest of the pipeline which could add significant value..... Exciting times ahead. Gl ; -)

SIRT6 Reported to Destabilize APP

19 Dec 2024

Why is age the strongest risk factor for Alzheimer’s disease? In the December 10 Science Signaling, scientists led by Ning Bai, Difei Wang, Yu Di, and Liu Cao at China Medical University in Shenyang, and Hua Liu at Jinzhou Medical University, offer a clue. They report that levels of sirtuin 6, a member of a family of proteins deacetylases, drop with age in human and mouse brain.

SIRT6 deacetylates three lysine residues in amyloid precursor protein.

As SIRT6 falls with age, APP rises.

A SIRT6 activator reduced plaque burden in mice.

The AD connection? SIRT6 deacetylates three adjacent lysines in amyloid precursor protein, and this post-translational modification offers APP up to the ubiquitin-proteasome system for degradation. As SIRT6 peters out, more APP remains to generate Aβ peptides. Indeed, co-first authors Bai and Rong Cheng also found that a SIRT6 activator reined in plaque burden in an APP/PS1 mouse model of AD.

hTtps://www.alzforum.org/news/research-news/sirt6-reported-destabilize-app

All set for a stellar 2025 with any luck...with plenty of potential positive newsflow stacking UP!!! Gla :-)

A nice lucrative deal for a UK biotech, and something similar for Genflow more than likely, given the importance and compelling nature of Sirt6's influence and therapeutic potential over multiple disease targets. Gla ;-)

GSK Forms Strategic Drug Development Deals with Relation and Muna

Dec 11, 2024

Under the two collaboration agreements with Relation, GSK will pay a total upfront payment of $45 million, comprising an equity investment of $15 million. Relation will be eligible to receive success-based collaboration payments of up to $63 million. It will also be eligible to receive potential preclinical, development, commercial, and sales milestone payments averaging $200 million per target across both deals as well as tiered royalties on net sales of products.

hTtps://www.biopharminternational.com/view/gsk-forms-strategic-drug-development-deals-relation-muna

Very interesting and extremely encouraging....game changing news at anytime!!! Gla ;-)

October 2024

"Multiple key clinical and regulatory milestones expected in next 18 months

Undervalued stock opportunity; Potential acquisition by pharmaceutical partner"

LONG LIFE IP

2 patent families SIRT6 centenarian and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)

GENE DELIVERY SYSTEMS

Proprietary innovative gene delivery systems: exo-AAV, mRNA exosomes, LNPs Centenarian variant of SIRT6 gene

GF-1002 and GF-1003

Multiple key clinical and regulatory milestones expected in next 18 months

Undervalued stock opportunity; Potential acquisition by pharmaceutical partner

WHO WE ARE

Pioneering Novel Gene Therapeutics for a Longer, Healthier Life

MISSION: aging is underlying risk factor for disease, and our aim is to deliver

gene therapeutics that potentially halt or slow the aging process in humans and dogs

SIRT6 GENE: longevity protein that widely regulates aging and immunity and

is a potential therapeutic target for the treatment of diseases

PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers

a centenarian variant of the SIRT6 gene for treatment of MASH

SEASONED TEAM: experienced and proven management with extensive

experience in public & private pharma and biotech

ROBUST PIPELINE: advancing multiple development programs

over 24 months: MASH, Sarcopenia, Werner and life extension of dogs

SIRT6: REPAIRING DNA

SIRT6 gene/protein repairs DNA damage (especially double strand breaks (DSB)) and prevents senescence of our cells

SIRT6 gene codes for SIRT6 protein

Stronger SIRT6: Longer lifespan

The Ability of SIRT6 to stimulate DSB repair corelates with maximum lifespan (MLS) in rodents

5 Amino Acids determine the differential activities of SIRT6

FOCUS ON CENTENARIAN SIRT6

SIRT6 centenarian variant gene has more efficient DNA repair properties

MASH PROGRAM

Affects est. 35 million people globally

• Increasing prevalence

• Leading cause of chronic liver disease and liver transplant

Significant unmet medical need

Clear regulatory accelerated development pathway.

EMA and FDA guidelines accept:

✓ Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH

✓ Histological changes are achievable within a 12-18-month time-frame

✓ Placebo control

✓ Conditional fast-track approval

EXOSOME DELIVERY SYSTEM: SAFE AND COST-EFFECTIVE

Genflow’s patent-pending technology has already been tested in several preclinical studies

ADVANTAGES: EXOSOME DELIVERY

Exo-AAV can mediate efficient, specific, and more durable SIRT6 expression in liver compared to conventional AAV

2023 KEY HIGHLIGHTS & 2024 PRIORITIES

GROWING IP PORTFOLIO

Provisional patent application in 2023 for editing SIRT6 gene, linked to longevity

and age-related diseases

EXPANDED MARKET

Awarded to new grants in 2023 & 2024 expanding research pipeline and size of

therapeutic markets

GF-1002

Undertaking key Investigational New Drug (IND) -enabling development activities

to help define pharmacological and toxicological properties and potential benefit

to NASH patients

GF-1003

Commencing preliminary discussions with the European Medicines Agency (EMA)

on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) targeting

Werner Syndrome

2023 KEY HIGHLIGHTS & 2024 PRIORITIES

LARGE MARKET OPPORTUNITY

NASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication

LONG LIFE IP

2 patent families SIRT6 centenarian and gene delivery (entering National Ph

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,781 followers

2h

Check out Genflow Biosciences (LON:GENF) (OTCQB:GENFF) latest presentation! Learn about #GENF's impressive financials, recent milestones in its #SIRT6 studies, and exciting future plans.

See it here: https://loom.ly/RsxnFCE

#biotech #MASH #WernerSyndrome #Sarcopenia #aging

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,782 followers

1h

🧬 The rise of exosome-based therapeutics has caused quite a stir in the #biotechnology field. 🧬

Earlier this year, BioSpace spotlighted the growing potential of the therapies. Recognized as a leader in the field, they turned to Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Dr. Eric Leire for his insights.

👀 Read what he had to say here: https://loom.ly/QeThahw

#GENF #GENFF

Exosome Therapeutics Are Paving a Path to Clinical Readiness

biospace.com

24/10/24

Roche, Dyno Launch $1B+ AAV Gene Therapy Vector Collaboration

Roche will apply Dyno Therapeutics’ engineered adeno-associated virus (AAV) capsid platform to develop next-generation AAV vectors for gene therapies targeting unspecified neurological diseases, through a collaboration that could generate more than $1 billion for Dyno.

The collaboration—the second for the companies—is designed to provide Roche with further access to Dyno’s platform and sequence design technologies enabling in vivo gene delivery.

Dyno and Roche launched their first collaboration in 2020, when they inked a research collaboration and license agreement for a potentially more-than-$1.8 billion partnership to develop next-generation AAV vectors for neurological disease and liver-directed gene therapies.

htTps://www.genengnews.com/topics/genome-editing/roche-dyno-launch-1b-aav-gene-therapy-vector-collaboration/

Fingers firmly crossed Northeast, and certainly very important news for the advancement of Genflow's clinical programmes. Gl :-)

ExoXpert will also be able to be the first CDMO internationally to offer exosome specialized GMP capabilities to its current client portfolio in both US and EU markets as well as future partners. ExoXpert can activate additional clean room on demand.

The GMP certification to be awarded to a specialist exosome CDMO is a significant international achievement. It allows EXO Biologics & ExoXpert to support across the industry clinical trials and regulatory submissions for the growing number of exosome-based products and services internationally. Currently, the greatest demand is for the use of exosome as safe and non-viral drug delivery system for cell & gene therapy applications.

Successful Loading of mRNA and DNA Payloads into GMP-Grade Exosomes

In addition to the production site certification, EXO Biologics and ExoXpert have successfully completed loading a number of chemical molecules and nucleic acids into exosomes from various cell sources. This breakthrough represents a critical step toward developing safe, efficient, and scalable exosome-based therapies for genetic material delivery.

Small molecules and short nucleic acids (siRNA and miRNA) have already been validated in an end-to-end GMP-like setting. Now EXO Biologics has made significant progress in loading larger molecules, such as mRNA and DNA, into GMP-grade exosomes for third-party non-viral drug delivery applications. Preliminary data from EXO Biologics’ trials show a retention rate up to 80% of the loaded DNA cargo upon exosome loading.

EXO Biologics and ExoXpert are now working together on optimization and GMP translation of this new unit operation to provide a seamless platform toward clinical application. The loading step is to be incorporated in ExoXpert’s cutting edge ExoPulse™ exosome manufacturing GMP platform. ExoPulse is currently being used by several partners to develop exosome-based product with a derisked path to clinical.

Genflow

· Exosome-mRNA project with EXO Biologics - which aims to deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, potentially leading to groundbreaking treatments for both diseases.

EXO Biologics & ExoXpert achieve two critical industry-first milestones for the exosome field

• First GMP certification of European exosome-specialist manufacturing facility

• Successful loading of mRNA and DNA payloads into GMP-grade exosomes for third-party non-viral drug delivery services

Liège, Belgium, December 2, 2024

– EXO Biologics and its CDMO subsidiary, ExoXpert, leading innovators in exosome-based therapeutics and drug delivery solutions, today announce ExoXpert is the first European CDMO specializing in exosomes to receive Good Manufacturing Practice (GMP) certification for its state of the art manufacturing plant.

In addition, EXO Biologics has managed to achieve the loading of GMP-grade exosomes with mRNA and DNA payloads, a major milestone for the development of exosome-based therapies.

These achievements are two significant milestones that will further solidify EXO Biologics’ position at the forefront of the maturing exosome field.

GMP Certification of Clean Rooms in Liège, Belgium

ExoXpert is the first European exosome specialist CDMO to receive Good Manufacturing Practice (GMP) certification.

The certification is for its exosome manufacturing plant in Liège, Belgium and has been awarded by the Belgian federal agency for medicines and health products.

The growth of EXO Biologics and ExoXpert has been strongly supported by BioWin (the health cluster of Wallonia) and SPW (Wallonia Public Service).

hTtps://www.exobio.be/en/news/16_exo-biologics-exoxpert-achieve-two-critical-industry-first-milestones-for-the-exosome-field

Plenty in the pipeline Porter for a potential stellar 2025 and exponential UPside from this rockbottom bargain basement low...Can't wait....in Eric we trust!!! Gl :-)

Eric estimated 6 months for Proof of Concept, and they already have a Vet Partner in place. Positive results should trigger an out-licensing deal, news of which would be transformational and an absolute game changer imho, as it should include upfront payments , milestones and royalties . The time line to market would be in the hands of the Vet Partner thereafter. Gl :-)

14th October 2024

"There's a very large appetite from the veterinary industry for life extension for our dog companions. Therefore, we'll provide proof of concept. We're starting this very soon, and once this proof of concept is finished, that should trigger an out-licensing deal with our partner in veterinary. "

Ditto Porter, and despite the current low sp, I'm sure the majority of listed sells this week's have been buys, given my bargain 1.58p top up...Looking forward to the next UPdate or two for some sustained UPward momentum. Gl :-)